A5094014164- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Dementia and Cognitive Impairment Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Amyotrophic Lateral Sclerosis Research
- Single-cell and spatial transcriptomics
- Neurological Disease Mechanisms and Treatments
- RNA regulation and disease
University of California, Santa Barbara
2023-2024
Universidad de Antioquia
2023-2024
Autopsy studies have demonstrated that comorbid neurodegenerative and cerebrovascular disease occur in the great majority of subjects with Alzheimer dementia (ADD), are likely to additively alter rate decline or severity cognitive impairment. The most important these Lewy body (LBD), TDP-43 proteinopathy disease, including white matter rarefaction (WMR) cerebral infarcts. Comorbidities may interfere ADD therapeutic trials evaluation clinical as they not respond AD-specific molecular...
Abstract INTRODUCTION This study investigates primary lateral sclerosis (PLS) as a rare manifestation of the presenilin 1 ( PSEN1 ) NM_000021 c.851C > T p.Pro284Leu variant in three siblings Colombian family, outlining its clinical and neuropathological features their relationship to Alzheimer's disease (AD). METHODS Data were gathered using evaluations, next‐generation genetic sequencing, magnetic resonance imaging, biomarker analysis, examination. RESULTS Carriers Pro284Leu exhibited...
Studying comorbidities in early onset Alzheimer disease (AD) may provide an advantageous perspective on their pathogenesis because aging factors be largely inoperative for these subjects. We compared AD between early-onset sporadic cases and American Colombian with PSEN1 mutations. neuropathological changes (ADNC) were very severe all groups but more the groups. Lewy body cerebral white matter rarefaction most common (up to 60%) of comorbidities, followed by arteriolosclerosis 37%),...